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We designed, implemented, and revised the Brigham Fracture Intervention Team (B-FIT) initiatives to improve in-hospital care
of fracture (Fx) patients. Eﬀectiveness was evaluated for 181 medical records of 4 cohorts in four successive years of consecutive
patients who were admitted with a fragility hip Fx. The Discharge Initiative (DI) (computer-based) includes 1200mg calcium
and 1000IU vitamin D3 daily. The Admission Initiative (AI) was introduced one year later with reminders for serum 25OHD
measurement, initiation of daily calcium (1200mg) and vitamin D (800IU), and an order for Endocrinology consultation, with
an amendment for a computer-assisted reminder and a dose of D2 (50 000IU). Initially, the computer-based DI was more eﬀective
(67%) than the surgeon-driven AI (33%, P<. 001). After introduction of a computer-assisted reminder, AI eﬀectiveness increased
to 68%. The marked prevalence of vitamin D insuﬃciency reaﬃrms the importance of incorporating vitamin D recommendations
in Fx care pathways.
1.Introduction
There is growing concern about the marked inadequacy of
osteoporosis care for patients who suﬀer a fragility (low-
energy) fracture [1]. Hip fractures increase exponentially
with age and are associated with impaired mobility, loss of
independence, increased hospitalizations, and mortality for
up to one in four women during the year following the
fracture [2]. Evidence shows that risk of fracture is increased
in those who have had a ﬁrst fracture [3] .Ar e p o r tf r o ma
Danish registry indicates that for patients with a hip fracture
there was a 6-fold increase in risk of second hip fracture for
women and a 9-fold increase for men [4]. An analysis of data
from two longitudinal studies in the United States showed
that hip fracture patients had a 2.5-fold increased risk of
subsequent self-reported fragility fracture other than hip [5].
IntheUnitedStates,althoughapproximately90%ofpatients
with hip fractures have osteoporosis, only 19% of them
receive postfracture evaluation or therapy for osteoporosis
[6]. Moreover, a survey of databases of health maintenance
organizations indicates that this is a widespread problem [7].
This study evaluates the eﬀectiveness of the Brigham
Fracture Intervention Team (B-FIT) initiatives, new in-
hospital care initiatives designed to address osteoporosis
evaluation and in-hospital management. These care path-
ways include a Discharge Initiative and several versions
of Admissions Initiatives. Because of our earlier ﬁnding
of vitamin D deﬁciency in patients admitted with a hip
fracture [8], these initiatives include elements to identify
and manage vitamin D deﬁciency. The goal is to attend to
underlying musculoskeletal pathology that resulted in the
fracture and to launch that care by the admitting orthopedic
surgeons.
ItiswellappreciatedthatprolongedvitaminDdeﬁciency
in adults results in osteomalacia and hypovitaminosis D
myopathy with diﬀuse pain, increased risk of falls and frac-
tures, and nondisplaced pseudofractures. In addition, hyper-
parathyroidism secondary to hypovitaminosis D increases
bone resorption and further reduces bone mineral density.
These consequences of chronic vitamin D deﬁciency, osteo-
malacia, osteopenia, and osteoporosis are each associated
with increased fracture risk [9–11].2 International Journal of Endocrinology
It was our goal to translate those clinically relevant
research ﬁndings into hospital-based initiatives to improve
the care of patients admitted with a fragility fracture. A
multidisciplinaryteamoforthopedicsurgeons,endocrinolo-
gists, and investigators developed and revised Admission and
DischargeInitiativestoevaluateandaddresstheosteoporosis
and vitamin D status of patients admitted with a fragility
fractureofthehip.Theresponsibleorthopedicsurgeonswere
trained to place the orders for hospital in patients. These
in-hospital care elements involved cooperation between
orthopedic surgeons and endocrinologists, clinician training
and reinforcement, and evolution with computer assistance.
Eﬀectiveness of these B-FIT initiatives was evaluated with
auditsoffourannualcohortsofpatients.Improvementswere
made in response to interim ﬁndings.
2. Methods
2.1. Study Population. With an IRB-approved protocol and
its annual review, medical records of patients ≥50 years of
age who were admitted with fragility fracture of the hip and
proximal femur were examined. Cohorts comprised patients
who were admitted during the last ﬁve months of each of
4 years in order to ensure comparable appraisals in light
of interim modiﬁcations made in the Admission Pathway
and potential seasonal variations. Revisions were introduced
early in calendar years so that they would be well established
by the time of the annual evaluation. Each patient’s record
was reviewed by a board-certiﬁed orthopedic surgeon to
verify that the fracture represented a fragility (low energy)
fracture. After review, patients with avascular necrosis (n =
2), high energy traumatic fracture (n = 3), or fracture of
unspeciﬁed etiology (n = 2) were excluded. A total of 181
subjects were included. In the Year 2 cohort, two patients
died of unrelated medical causes while in hospital and thus
werenotavailableforanalysisofDischargeeﬀectiveness.One
in-hospital death occurred in the Year 4 cohort.
2.2. B-FIT Admission and Discharge Initiatives. The ﬁrst
surgeon-initiated initiative was introduced as additions to
the pre-existing computer-based discharge order-set for
fracture patients. The B-FIT Discharge Initiative prompts
the surgeon to give written and oral instructions for daily
calcium with vitamin D (600mg elemental calcium with
200IU vitamin D3, bid), a daily multivitamin (with 400IU
vitamin D3 and 66mg calcium), additional daily vitamin D
(400IU vitamin D3), and an outpatient osteoporosis evalua-
tion (Table 1). The total amount of supplemental vitamin D3
is 1200IU daily. The total amount of supplemental calcium
is 1240mg daily.
The Admission Initiative was introduced early in year 1
in the form of a training session for orthopedic attendings
and residents, distribution of laminated pocket cards, and
follow-up emails to train the rotating orthopedic residents.
It instructs the surgeon to order tests for serum calcium,
albumin, and 25-hydroxyvitamin D [25OHD] (Nichols
Advantage prior to January 1, 2005; thereafter DiaSorin
Liaison), to start daily calcium carbonate with vitamin D3
(600mg elemental calcium with 200IU vitamin D3, bid),
a daily multivitamin (with 400IU vitamin D3 and 66mg
calcium), and to order an Endocrinology consultation. The
total daily dose of supplemental vitamin D3 was 800IU
during hospitalization.
In early Year 3, amendments to the Admission Initia-
tive were implemented. A computer-assisted reminder was
deployed to appear as a pop-up screen in the fracture service
database program when the details of the admission were
entered and met the study criteria (fragility fracture of the
hip/femur and age ≥50 years). The amendment also added
the order for administration of one oral dose of 50,000IU
vitamin D2.
2.3. Measures of Eﬀectiveness. With IRB approval and annual
review, medical records were inspected for past medical
history, elements of admission and discharge instructions,
and details of the discharge regimen.
Eﬀectiveness of Admission Initiative was deﬁned as the
percent of patients who had a measurement of 25OHD
during hospitalization. Median values of 25OHD were
calculated for each cohort. Vitamin D insuﬃciency was
deﬁned as <32ng/mL 25OHD. Secondary analyses were
made of percents of subjects with a record of an Endocrine
consultation, of administration of 50,000IU vitamin D2
while hospitalized, or with a record of past medical history
of a diagnosis of osteoporosis. Eﬀectiveness of Discharge
Initiative was deﬁned as the percent of patients who were
provided with instructions for calcium/vitamin D.
2.4. Statistical Analysis. Statistical analysis was performed
with GraphPad InStat version 3.00 for Windows 95, Graph-
PadSoftwareInc.(www.graphpad.com).Categoricaldataare
reported as frequencies and continuous data are reported as
the mean ± standard deviation, unless otherwise speciﬁed.
Comparisons of frequencies were made with Fisher’s Exact
Test (http://www.langsrud.com/ﬁsher.htm) . All P-values are
two-sided.
3. Results
Cohorts of 57, 41, 42, and 41 subjects fulﬁlled the study
criteria (fragility fracture of the femur and older than 50
years) in the designated period in years 1, 2, 3, and 4,
respectively (Table 1). These cohorts included 74 to 82%
women. Review of comorbidities prior to hospitalization for
fracture revealed that 15% had a pre-existing diagnosis of
osteoporosis and 17% had a diagnosis of hypothyroidism.
Of the subjects that had been tested for serum 25OHD
concentration, 78% were found to be insuﬃcient, having
serum levels <32ng/mL. 48% had serum 25OHD levels
≤20ng/mL, the level commonly used to deﬁne vitamin D
deﬁciency; 35% had serum 25OHD levels ≤15ng/mL, a level
of severe deﬁciency.
Eﬀectiveness of the Admission Initiative was 33% in
the months following its introduction. After deployment
of a computer-assisted reminder early in year 2, there
was an increase in Admission eﬀectiveness, reaching 68%International Journal of Endocrinology 3
Table 1: Comparison of eﬀectiveness of B-FIT admission and discharge initiatives in subjects admitted with hip fragility fracture. (i)
Admission initiative was introduced early in Year 1; (ii) admission initiative was modiﬁed early in Year 2 with a computer-assisted reminder;
(iii) discharge initiative was introduced one year before Year 1 with computer-based directives.
Year 1 cohort Year 2 cohort Year 3 cohort Year 4 cohort
Number of subjects 57 41 42 41
Age (years, mean ± SD, median) 77.5 ±11.07 3 .9 ±12.87 9 .2 ±10.77 9 .1 ±11.8
81 74 82 81
Percent, number women 74%, 42 71%, 29 76%, 32 78%, 32
Eﬀectiveness of admission initiative 33% (19/57) 41% (17/41) 57% (24/42) 68% (28/41)
Analysis of eﬀectiveness of admission initiative; P-values
.524 versus Year 1 .024 versus Year 1 .001 versus Year 1
.190 versus Year 2 .026 versus Year 2
.040 versus Years 1 and 2 .366 versus Year 3
.001 versus Years 1 and 2
Eﬀectiveness of discharge initiative 67% (38/57) 82% (32/39) 83% (35/42) 80% (32/40)
Analysis of eﬀectiveness of discharge initiative; P-values
.108 versus Year 1 .07 versus Year 1 .17 versus Year 1
1.00 versus Year 2 1.00 versus Year 2
1.00 versus Years 1 and 2 .78 versus Year 3
.52 versus Years 1 and 2
eﬀectivenessinyear4(P = .001).Additionalanalysesshowed
anincreaseinpercentofEndocrineconsultationsfrom7%in
year 1, to 22% in year 2, to 34% in year 3, and 48% in year 4.
After introduction of the element to administer a single oral
dose of 50,000IU of vitamin D2, 29% of the subjects received
this treatment, whereas the percent was 52% in year 3 and
54% in year 4.
Eﬀectiveness of the computer-assisted Discharge Initia-
tive in year 1 was 67%. This was signiﬁcantly greater than
the 33% eﬀectiveness of the then-newer surgeon-driven
Admission Initiative (P<. 001). In year 1, the Discharge
Initiative had been in use for a year more than the Admission
Initiative. In addition, the Discharge Initiative was computer
prompted from its introduction. With time, there were
further increases in Discharge eﬀectiveness with statistical
trendsbutnotsigniﬁcance.Byyear3,theDischargeInitiative
had reached an eﬀectiveness level of 83%. On the basis of
having a report during hospitalization of very low 25OHD
and an in-hospital consultation with an endocrinologist,
many patients were discharged with a regimen that included
aprescriptionfor50,000IUvitaminD2 perweekfor8weeks,
to initiate correction of the deﬁciency.
4. Discussion
This study describes our four-year experience in transform-
ing the care of fragility fractures of the femur. Our B-
FIT program development was greatly enhanced through
multidisciplinary interactions and deployment of hospital-
based computer-assisted enhancements of the Admission
and Discharge Initiatives at Brigham and Women’s Hospital.
Eﬀectiveness of these surgeon-driven orders was enhanced
with computer-based tools. Recent launching of prewrit-
ten order sets is expected to further improve in-hospital
management of osteoporosis. Many hospitals now have care
improvement services that can expedite this.
Analysis of the Year 1 cohort revealed that the eﬀec-
tiveness of the Discharge Initiative (67%) was twice that
of the Admission Initiative (33%, P<. 001). This ﬁnding
is attributable to the fact that the Discharge Initiative was
implemented one year earlier than the Admission Initiative,
and that the Discharge Initiative was integrated into the
hospital computer-based discharge-order system. Greater
clinician familiarity and education can contribute to the
yearly increases in both pathways.
The ﬁrst mechanism that was used to introduce the
Admission Initiative consisted of training sessions for ortho-
pedic attendings and residents, laminated pocket cards,
and periodic email reminders. Feedback from residents
indicated that it was inconvenient to manually integrate the
information on the cards with the hospital’s computer-based
order system. This led to an enhancement of the Initiative.
In early year 2, a pop-up screen displaying the Admission
Initiative was developed for the orthopedic trauma service
database program to be activated upon entry of the details
of the admission that met the study criteria. Eﬀectiveness
increased in each subsequent cohort.
The ﬁnding of vitamin D insuﬃciency in this study is
consistent with other investigations of patients with fragility
fractures. In an evaluation of United States community-
living postmenopausal women with hip fracture and no
causes of secondary osteoporosis, we reported that 50%
of them had extreme vitamin D deﬁciency (25OHD ≤
12ng/mL) [8]. With the current threshold of 32ng/mL, 90%
of those subjects are classiﬁed as vitamin D insuﬃcient [12].
In a larger study of 110 women in Boston and Baltimore
with fragility fracture of the hip, vitamin D insuﬃciency was
deﬁned by the more recent threshold (<32ng/mL), which
was present in 96% [12]. Our recent report of a series of
consecutive patients with fragility fractures showed vitamin
Ds u ﬃciency in only 22% [13]. A recent multinational study
showed that 90% of 385 subjects with a hip fracture had
serum 25OHD levels <32ng/mL [14]. This reaﬃrms that4 International Journal of Endocrinology
vitamin D insuﬃciency is an international concern for hip
fracture patients. A United States study of women and men
with fragility fracture of the hip, humerus, spine, rib, or
wrist indicated that nearly all had vitamin D insuﬃciency
[15]. Likewise, analysis of data from NHANES III showed
that serum 25OHD was signiﬁcantly related to reduced hip
fractures in non-Hispanic white adults >65 year of age [16].
Data associating lower vitamin D levels with reduced muscle
strength and increased risk of falls [17]a sw e l la se v i d e n c e
for reduced lower extremity function one year after a hip
fracture [12] provide additional impetus for ensuring that
hip fracture patients are evaluated and optimally treated for
vitamin D insuﬃciency.
Early in year 2, the Admission Initiative was amended
to include administration of a single oral dose of 50,000IU
vitamin D2, the most available and inexpensive form of
high-dose vitamin D. The rationale to initiate correction
of vitamin D status as soon as possible was twofold: to
ensure proper healing of the fracture and to address the
underlying skeletal disease and risk of falls and subsequent
fractures. Risk for fracture nonunion is also associated with
metabolic and endocrine abnormalities. In a recent study in
which adult patients with unexplained fracture nonunion
were evaluated by an endocrinologist, the most common
new diagnosis was vitamin D deﬁciency (68%), followed
by thyroid abnormalities (24%), and hypogonadism (22%)
[18]. In this study, history of hypothyroidism was noted
in 13% of the hip fracture patients. Epidemiological data
indicate the relationship between low vitamin D status and
risk of falls and fracture [19]. A recent meta-analysis of
the literature from randomized controlled trials revealed
that trials that had used 700 or 800IU per day of vitamin
D plus calcium showed eﬃcacy in reducing fracture risk
by 26%, compared with calcium or placebo, whereas trials
with 400IU vitamin D/day were not eﬀective [20]. This was
reaﬃrmed in a larger meta-analysis that included data from
63 897 individuals [21]. Furthermore, from publications that
included measurement of serum 25OHD, it is clear that
antifractureeﬃcacyincreaseswithhigherachieved25(OH)D
levels; levels above 30ng/mL were achieved with 700–800IU
vitamin D3 [19].
There is some information about the co-occurrence of
osteomalacia and osteoporosis in the elderly. Osteomalacia
is diagnosed as the presence of excess osteoid and decreased
mineralizing surfaces by histomorphometric analysis of
nondecalciﬁed histology. In a 1974 publication, histological
osteomalacia in iliac crest biopsies was reported in 17% of
womenand39%ofmenatthetimeofproximalfemoralfrac-
ture [22]. In a 1990 histomorphometric analysis of iliac crest
biopsies in elders with femoral neck fracture, osteoporosis
was present in 71% and osteomalacia in 29% [23]. A recent
histomorphometric study of biopsies from osteoporotic
subjects showed an increase in osteoid thickness that was
inversely correlated with serum 25OHD and emphasizes the
importance of avoiding vitamin D insuﬃciency [24].
Although there are clinical tools to diagnose and ther-
apeutic options to treat low bone density, osteoporosis
remains underdiagnosed and seriously undertreated. Bar-
riers to diagnosis and care of osteoporosis in patients
with fragility fractures include uncertainties about clinical
responsibility, the need for multidisciplinary medical teams,
implementing computer-based tools, clinical expertise as
recommendations for osteoporosis care evolve, and impact
of other comorbidities upon treatment plan.
Various means have been suggested to enhance osteo-
porosis care in fracture patients, including interventions by
primary care practitioners [25] and in outpatient postfrac-
ture clinical settings [26, 27] .I nar e c e n tr e p o r tf r o ma
community-based multispecialty partnership, the delivery of
osteoporosis care was increased after developing an informa-
tion systems enhancement that automatically referred ortho-
pedic fracture patients to an osteoporosis care service [28].
Less has been published about in-hospital initiatives, as
they generally require paradigm shifts in large organizations.
A retrospective analysis of hip fracture patients admitted
to a tertiary care academic medical center in the United
States showed that 17% were discharged on calcium in 2000,
compared with 4% in 1995 [29]. In a series of patients
hospitalized for fragility hip fracture in 2000, 10 of 75 (13%)
were given a new prescription for osteoporosis medication
while hospitalized [30]. A subsequent randomized study
f r o mt h a tt e a mc o m p a r e de ﬀectiveness of two interventions
during hospitalization: in the control intervention, patients
receivedapamphletonfallprevention;inthestudyinterven-
tion, patients had a 15-minute discussion about osteoporosis
evaluation with a research nurse and were provided with
a list of questions for their primary medical physician
about osteoporosis evaluation and treatment, followed with
a telephone reminder 6 weeks after hospitalization about the
needtoaddressosteoporosis[31].Evaluationbytelephoneat
6 months showed that 42% of those in the study group had
received attention for osteoporosis, compared with 19% in
thecontrolgroup.Successwasattributedtotheimpactofthe
research nurse’s activities. Another osteoporosis consultation
team reported that 53% of 59 patients with fragility hip
fracture were not seen by the team because the initiating
consultation request was not made [32]. Evaluation of
three care models in diﬀerent health-care environments also
concluded that eﬀectiveness increased when new personnel,
such as an osteoporosis nurse practitioner, assumed the
responsibility of coordinating patient education, laboratory
tests, and communication between orthopedic staﬀ and
primary care physicians [33]. A pilot initiative from the
American Orthopaedic Association used web-based training
of orthopedic surgeons for process improvement measures
and patient counseling, including calcium and vitamin D
[34]. Those interventions had little eﬀect on measures
of osteoporosis management, but resulted in signiﬁcant
improvements in counseling and documenting the patients’
osteoporosisriskfactors.Expansionofthatprogramwassaid
to require new support mechanisms or personnel to ensure
that presentation with an osteoporotic fracture launches
appropriate standard of osteoporosis care [34].
This study highlights the importance of vitamin D
in patients with fragility fractures. Identifying and cor-
recting underlying osteoporosis in patients who present
with fragility fracture are aimed to reducing the risk for
additional fractures and disability [35, 36]. The consultingInternational Journal of Endocrinology 5
endocrinologist is the team member who is responsible
for evaluating potential causes of secondary osteoporoses,
in light of information that 80% or more hip fracture
patients have medical conditions that are associated with
increased fracture risk [36]. An in-hospital report of 25OHD
≤ 20ng/mL is addressed with an additional 50,000IU
ergocalciferol before discharge and then 50,000IU per week
for another 6 weeks with retesting thereafter. An in-hospital
level of 20 to 25ng/mL is addressed with a prescription
for 50,000 units twice per month. Higher doses of vita-
min D repletion over shorter intervals are used by some
physicians. The consulting endocrinologist also assesses risk
for hypercalcemia, hypercalciuria, and nephrolithiasis with
calcium and creatinine values and identiﬁes patients with
other contraindications for high-dose vitamin D, including
sarcoidosis or granulomatous disease. Hypercalcemia is rare
in the settings of hypovitaminosis D and low urinary
calcium excretion, and, as we reported for an earlier series,
patients with hip fracture tend to have lower circulating
calcium levels than age and gender matched controls [8].
The endocrinologist also discusses with the patient the need
for posthospitalization osteoporosis evaluation and manage-
ment. An in-hospital prescription for weekly ergocalciferol is
automatically carried forward into the discharge summary.
In this study, only 15% of subjects had a previous diag-
nosisofosteoporosisandsomepatientswereadmittedwitha
previous prescription for bisphosphonates. There are caveats
to initiating antiresorptive osteoporosis medications during
hospitalization for fragility fracture. The ﬁrst concerns the
evaluation and correction of vitamin D deﬁciency. Evidence
indicates that bisphosphonates may produce hypocalcemia
in the presence of vitamin D insuﬃciency [37] and that
responsiveness to bisphosphonate is reduced in the pres-
ence of secondary hyperparathyroidism with vitamin D
insuﬃciency [38]. Zoledronic acid (5mg infusion once per
year) is an option for patients with a recent hip fracture
and is FDA-approved for secondary prevention of fractures.
Recent evidence evaluating the timing of zoledronic acid
administration post-hip fractureindicates decreasedfracture
reduction eﬃcacy in subjects treated “within 2 weeks of their
fracture repair,” compared with later treatment [39].
There is some information from animal studies about
bisphosphonates not inhibiting early stages of fracture
healing. Studies in ovariectomized rat models showed that
administration of alendronate at the time of fractureresulted
in larger callus formation, but with more woven than lamel-
lar bone compared with control ovariectomized animals
[40]. In a study with rats, a single dose of 14carbon-labeled
zoledronic acid after a fracture demonstrated the greatest
accumulation in the external fracture callus [41]. Although
the clinical signiﬁcance of those ﬁndings is not known,
there is a concern that early intravenous administration of
zoledronic acid would lead to greater uptake at the fracture
sitethanintherestoftheskeletonandpossiblyinterferewith
remodeling and maturation of the healing bone.
In vitamin D suﬃcient hip fracture patients, in the
absence of contraindications like esophagitis or gastric
disorders, it may be practical to initiate therapy with oral
bisphosphonates upon hospital discharge. It is not advisable
to initiate annual intravenous bisphosphonate while in the
hospital. For all bisphosphonates, vitamin D suﬃciency
should be documented before initiation of therapy; for
intravenouszoledronicacid,itmaybeconvenienttoschedule
the follow-up vitamin D test and the infusion at the time of
outpatient appointments with the orthopedic surgeon or the
endocrinologist.
In conclusion, eﬀectiveness of in-hospital Admission and
Discharge Initiatives requires communication and cooper-
ation among orthopedic surgeons, endocrinologists, and
other physicians, training and reinforcement, computer
assistance, audits, and evolution. This study shows the
beneﬁcial results of self-evaluation and systems analyses to
identify opportunities for improvement. The prevalence of
vitamin D insuﬃciency observed in this study reaﬃrms the
importance of incorporating vitamin D recommendations
in fragility fracture care initiatives. Orthopedic surgeons
who treat patients with acute fragility fracture are in ideal
position to initiate in-hospital multidisciplinary care path-
ways aimed at reducing the sequelae and preventing other
fractures.
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